JW Pharmaceutical Corp (001065) - Total Assets
Based on the latest financial reports, JW Pharmaceutical Corp (001065) holds total assets worth ₩611.56 Billion KRW (≈ $414.44 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore JW Pharmaceutical Corp (001065) long-term investment share to see how much of total assets are deployed in long-term investments.
JW Pharmaceutical Corp - Total Assets Trend (2014–2024)
This chart illustrates how JW Pharmaceutical Corp's total assets have evolved over time, based on quarterly financial data. Check financial resilience of JW Pharmaceutical Corp to evaluate the company's liquid asset resilience ratio.
JW Pharmaceutical Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
JW Pharmaceutical Corp's total assets of ₩611.56 Billion consist of 50.7% current assets and 49.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 1.7% |
| Accounts Receivable | ₩135.50 Billion | 22.4% |
| Inventory | ₩111.73 Billion | 18.5% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩40.84 Billion | 6.8% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how JW Pharmaceutical Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see JW Pharmaceutical Corp stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: JW Pharmaceutical Corp's current assets represent 50.7% of total assets in 2024, a decrease from 58.3% in 2014.
- Cash Position: Cash and equivalents constituted 1.7% of total assets in 2024, up from 0.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 1.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 22.4% of total assets.
JW Pharmaceutical Corp Competitors by Total Assets
Key competitors of JW Pharmaceutical Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
|
China | CN¥5.95 Billion |
JW Pharmaceutical Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.51 | 1.42 | 1.28 |
| Quick Ratio | 0.98 | 0.96 | 0.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩111.85 Billion | ₩106.27 Billion | ₩64.58 Billion |
JW Pharmaceutical Corp - Advanced Valuation Insights
This section examines the relationship between JW Pharmaceutical Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -6.3% |
| Total Assets | ₩604.60 Billion |
| Market Capitalization | $335.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values JW Pharmaceutical Corp's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: JW Pharmaceutical Corp's assets decreased by 6.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for JW Pharmaceutical Corp (2014–2024)
The table below shows the annual total assets of JW Pharmaceutical Corp from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩604.60 Billion ≈ $409.73 Million |
-6.27% |
| 2023-12-31 | ₩645.04 Billion ≈ $437.13 Million |
+2.72% |
| 2022-12-31 | ₩627.97 Billion ≈ $425.57 Million |
-0.80% |
| 2021-12-31 | ₩633.05 Billion ≈ $429.01 Million |
+15.29% |
| 2020-12-31 | ₩549.09 Billion ≈ $372.11 Million |
-4.21% |
| 2019-12-31 | ₩573.21 Billion ≈ $388.45 Million |
-3.47% |
| 2018-12-31 | ₩593.79 Billion ≈ $402.40 Million |
-5.88% |
| 2017-12-31 | ₩630.87 Billion ≈ $427.53 Million |
-3.10% |
| 2016-12-31 | ₩651.08 Billion ≈ $441.23 Million |
+6.13% |
| 2015-12-31 | ₩613.48 Billion ≈ $415.75 Million |
+4.11% |
| 2014-12-31 | ₩589.24 Billion ≈ $399.32 Million |
-- |
About JW Pharmaceutical Corp
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more